The scientific manuscript “Patient-reported Impact of Axial Spondyloarthritis on Working Life: Results from the EMAS survey” has been accepted for publication in the journal Arthritis Care & Research. The research, which analyzes data from the International Axial Spondyloarthritis Map (EMAS), focuses on the impact of the disease on the employment status and working conditions of…
A total of 2166 patients with axial spondyloarthritis belonging to the EMAS study were evaluated. Of these patients, 60.7% reported mental problems, especially in those patients with higher disease activity, with anxiety and depression, those who were unemployed or on sick leave, those with greater functional limitation and younger patients. This study is published in…
A total of 680 patients with axial spondyloarthritis in Spain vs. 2166 with axial spondyloarthritis in 12 European countries were evaluated. With respect to the rest of European patients, Spanish patients showed a longer diagnostic delay (8.5 vs 7.2), higher disease activity (5.7 vs 5.4), and a higher unemployment rate (21.7% vs 9.2%). In addition,…
The results of the first phase of the REUMAVID study were presented on Monday, April 14, 2021 at the British Society for Rheumatology Annual Conference (BSR 2021). The interest raised by the study has led to it being selected for several activities: an ePoster presenting the study data for the UK sample (“Evaluation of the…
The diagnostic delay of the 2652 patients belonging to 13 European countries belonging to the European map of axial spondyloarthritis (EMAS) was 7.4 years. Furthermore, this diagnostic delay was associated with younger age at symptom onset, female gender, a higher number of visits to specialists before diagnosis and being diagnosed by a rheumatologist. This study…
The International Map of Axial Spondyloarthritis (IMAS) has been chosen as the winner of the Connecting Healthcare 2021 Award from more than 60 entries from across Europe from a variety of collaborative projects. The Connecting Healthcare Award is an initiative of the European Federation of Pharmaceutical Industries and Associations (EFPIA) that seeks to highlight innovative…
A total of 468 patients with migraine were analyzed, of whom 38.5% had migraine 15 or more days per month. The risk of anxiety was higher in patients suffering from migraine 3 or more days per month, while those with 19 or more migraine days per month were at risk of depression. In addition, patients…
After the Cypriot League Against Rheumatism (CYPLAR), the patient association leading the Cypriot part of the REUMAVID project, sent the first press release with the main findings of the REUMAVID study to the media, TV channels contacted them to interview them about the study and its objectives. Souzi Makri, President of CYPLAR and partner and…
A new article from the IMAS project, entitled “Gender differences in Patient Journey to Diagnosis and Disease Outcomes: results from the European Map of Axial Spondyloarthritis (EMAS)” has been published in the journal Clinical Rheumatology. Historically, axSpA has been conceived as a predominantly male disease, which could imply a bias during diagnosis and treatment of…
The costs of 475 migraine patients in Spain were analyzed, resulting in a total annual cost of €16,578.2 for patients with chronic migraine and €6,227.8 for patients with episodic migraine. In addition, a higher degree of disability, according to MIDAS, significantly increased the total cost of migraine, while the presence of psychiatric comorbidity increased costs…
